CRISPR Therapeutics AG is a biopharmaceutical company focused on developing CRISPR/Cas9-based gene editing therapeutics. Its lead product, CASGEVY (exagamglogene autotemcel), received the world's first approval of a CRISPR-based therapy in 2023 for sickle cell disease and transfusion-dependent beta thalassemia, developed in collaboration with Vertex Pharmaceuticals. The company also pursues in vivo editing, allogeneic CAR T cell therapies for autoimmune and oncology indications, and regenerative medicine programs.
Q2 FY2026 — expected 2026-08-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001193125-26-048957 | EDGAR | 125K words |
| 2025-02-11 | 2024-12-31 | 0000950170-25-017899 | EDGAR | — |
| 2024-02-21 | 2023-12-31 | 0000950170-24-017571 | EDGAR | — |
| 2023-02-21 | 2022-12-31 | 0000950170-23-003441 | EDGAR | — |
| 2022-02-15 | 2021-12-31 | 0000950170-22-001282 | EDGAR | — |
| 2021-02-16 | 2020-12-31 | 0001564590-21-006074 | EDGAR | — |
| 2020-02-12 | 2019-12-31 | 0001564590-20-004355 | EDGAR | — |
| 2019-02-25 | 2018-12-31 | 0001564590-19-004115 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001564590-18-004920 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001564590-17-003977 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-273337 | EDGAR | 28K words |
| 2025-08-04 | 2025-06-30 | 0000950170-25-102052 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064468 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121105 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0000950170-24-090746 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055719 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059476 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0000950170-23-039075 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018811 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000950170-22-020845 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015256 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008495 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-16 | 0001193125-26-108333 | EDGAR | 55K words |
| 2026-03-11 | 0001193125-26-101073 | EDGAR | — |
| 2026-02-12 | 0001193125-26-048873 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009880 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273329 | EDGAR | — |
| 2025-10-15 | 0001193125-25-240282 | EDGAR | — |
| 2025-08-04 | 0000950170-25-102027 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090170 | EDGAR | — |
| 2025-06-09 | 0000950170-25-083799 | EDGAR | — |
| 2025-05-19 | 0000950170-25-074428 | EDGAR | — |
200 total filings indexed. 168 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001674416 |
| Ticker | CRSP |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | V8 |
| Website | https://www.crisprtx.com |
| Listed | 2016-10-19 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report